These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 12739340)

  • 21. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
    Cheson BD
    Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
    Chiusolo P; Sica S; Leone G
    Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in bronchopulmonary and pleural cancers].
    Bourguet P;
    Bull Cancer; 2003 Feb; 90 Spec No():S23-41. PubMed ID: 12739334
    [No Abstract]   [Full Text] [Related]  

  • 24. Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care.
    Kaplan LD
    Am J Med; 2002 Mar; 112(4):320-1. PubMed ID: 11893374
    [No Abstract]   [Full Text] [Related]  

  • 25. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
    Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
    Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients].
    Cremerius U; Fabry U; Kröll U; Zimny M; Neuerburg J; Osieka R; Büll U
    Nuklearmedizin; 1999; 38(1):24-30. PubMed ID: 9987778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atypical thoracic and supraclavicular FDG-uptake in patients with Hodgkin's and non-Hodgkin's lymphoma.
    Döbert N; Menzel C; Hamscho N; Wördehoff W; Kranert WT; Grünwald F
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):33-8. PubMed ID: 15195002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early restaging positron emission tomography with 18F-fluorodeoxyglucose in aggressive non-Hodgkin's lymphomas: is it too easy to be true?
    Balzarotti M; Magagnoli M; Santoro A
    Ann Oncol; 2003 Jul; 14(7):1155-6. PubMed ID: 12853364
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of PET imaging in lymphoma.
    Burton C; Ell P; Linch D
    Br J Haematol; 2004 Sep; 126(6):772-84. PubMed ID: 15352980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
    Kumar R; Maillard I; Schuster SJ; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.
    Okada J; Yoshikawa K; Imazeki K; Minoshima S; Uno K; Itami J; Kuyama J; Maruno H; Arimizu N
    J Nucl Med; 1991 Apr; 32(4):686-91. PubMed ID: 2013808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of FDG positron emission tomography imaging on the management of lymphomas.
    Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
    Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Value of positron emission tomography in treatment of lymphoma patients].
    Kuwert T
    Strahlenther Onkol; 2001 Mar; 177(3):160-1. PubMed ID: 11285774
    [No Abstract]   [Full Text] [Related]  

  • 34. Positron emission tomography in the management of lymphomas: a summary.
    O'Doherty MJ; Hoskin PJ
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S128-30. PubMed ID: 12692689
    [No Abstract]   [Full Text] [Related]  

  • 35. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma.
    Schiepers C; Filmont JE; Czernin J
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S82-8. PubMed ID: 12719922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
    Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow.
    Elstrom RL; Tsai DE; Vergilio JA; Downs LH; Alavi A; Schuster SJ
    Clin Lymphoma; 2004 Jun; 5(1):62-4. PubMed ID: 15245610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revised response criteria for malignant lymphoma.
    Cheson BD; Pfistner B; Juweid ME; Gascoyne RD; Specht L; Horning SJ; Coiffier B; Fisher RI; Hagenbeek A; Zucca E; Rosen ST; Stroobants S; Lister TA; Hoppe RT; Dreyling M; Tobinai K; Vose JM; Connors JM; Federico M; Diehl V;
    J Clin Oncol; 2007 Feb; 25(5):579-86. PubMed ID: 17242396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of positron emission tomography in diagnosing subcutaneous panniculitis-like T-cell lymphoma.
    Bennani-Baiti B; Yadav S; Flynt L; Bennani-Baiti N
    J Clin Oncol; 2015 Apr; 33(10):1216-7. PubMed ID: 25691676
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.